On June 18, 2021, CARsgen Therapeutics Holdings Limited (hereinafter referred to as "CARsgen Therapeutics") was officially listed on the main board of the Stock Exchange of Hong Kong with an issue price of HKD 32.8 per share and gross proceeds of over HKD 3.1 billion, the largest Chapter 18A IPO in 2021 up to CARsgen Therapeutics’ listing.

As the PRC legal adviser and the PRC IP counsel for CARsgen Therapeutics, Global Law Office provided all the PRC related legal services on the public offering and listing, including but not limited to legal due diligence, research and demonstration on key legal issues, liaison with regulatory authorities, issuing legal opinions, IP due diligence and FTO, review, discussion, and modification of prospectus.

CARsgen Therapeutics is a biopharmaceutical company with operations in China and the U.S., focusing on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. CARsgen Therapeutics has internally developed novel technologies and a product pipeline with global rights and obtained 7 IND clearances for CAR-T therapies in China, the United States and Canada, ranking the first among all CAR-T companies in China, till now. In addition, CARsgen Therapeutics is the first in the world to successfully identify, validate and report Claudin 18.2 and glypican-3 as tumor-associated antigens for CAR-T therapies for gastric/pancreatic cancer and hepatocellular carcinoma, each of which represents significant unmet medical needs.

Liu Jingrong and Liu Zhan took the lead in providing the services. Other team members include Zhan Jingxin, Zhu Ruiqing, Li Bing, and Liu Yuanyi. Ma Degang, patent agent and Yao Zhengyang, patent agent, took the lead in providing IP related legal services.